This database contains 35 studies, archived under the term: "doubleblind method"
Click here to filter this large number of results.
DNA methylation and cognitive functioning in healthy older adults
Schiepers, Olga J. G.,
van Boxtel, Martin P. J.,
de Groot, Renate H. M.,
Jolles, Jelle,
Kok, Frans J.,
Verhoef, Petra,
Durga, Jane
Long-term supplementation with folic acid may improve cognitive performance in older individuals. The relationship between folate status and cognitive performance might be mediated by changes in methylation capacity, as methylation reactions are important for normal functioning of the brain. Although aberrant DNA methylation has been implicated in neurodevelopmental disorders, the relationship between DNA methylation status […]
Pilot study of granulocyte-colony stimulating factor for treatment of Alzheimer’s disease
Sanchez-Ramos, Juan,
Cimino, Cynthia,
Avila, Ross,
Rowe, Amanda,
Chen, Ren,
Whelan, Glenn,
Lin, Xiaoyang,
Cao, Chuanhai,
Ashok, Raj
Human granulocyte colony-stimulating-factor (G-CSF) is widely used for treatment of neutropenia and to mobilize stem/progenitor cells for bone marrow transplantation. In studies of thousands of healthy donor subjects treated with G-CSF to mobilize stem/progenitor cells, the side-effect profile has been reported to be mild and reversible. In pre-clinical studies, G-CSF was reported to improve spatial […]
Effects of a diet integration with an oily emulsion of DHA-phospholipids containing melatonin and tryptophan in elderly patients suffering from mild cognitive impairment
Rondanelli, Mariangela,
Opizzi, Annalisa,
Faliva, Milena,
Mozzoni, Marco,
Antoniello, Neldo,
Cazzola, Roberta,
Savarè, Rita,
Cerutti, Renata,
Grossi, Enzo,
Cestaro, Benvenuto
Age-related changes in nutritional status can play an important role in brain functioning. Specific nutrient deficiencies in the elderly may exacerbate pathological processes in the brain. Consequently, the potential of nutritional intervention to prevent or delay cognitive impairment and the development of dementia is an important topic. A randomized, double-blind, placebo-controlled trial has been performed […]
Amyloid-β(1-15/16) as a marker for γ-secretase inhibition in Alzheimer’s disease
Portelius, Erik,
Zetterberg, Henrik,
Dean, Robert A.,
Marcil, Alexandre,
Bourgeois, Philippe,
Nutu, Magdalena,
Andreasson, Ulf,
Siemers, Eric,
Mawuenyega, Kwasi G.,
Sigurdson, Wendy C.,
May, Patrick C.,
Paul, Steven M.,
Holtzman, David M.,
Blennow, Kaj,
Bateman, Randall J.
Amyloid-β (Aβ) producing enzymes are key targets for disease-modifying Alzheimer’s disease (AD) therapies since Aβ trafficking is at the core of AD pathogenesis. Development of such drugs might benefit from the identification of markers indicating in vivo drug effects in the central nervous system. We have previously shown that Aβ(1-15) is produced by concerted β-and […]
Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab
Ostrowitzki, Susanne,
Deptula, Dennis,
Thurfjell, Lennart,
Barkhof, Frederik,
Bohrmann, Bernd,
Brooks, David J.,
Klunk, William E.,
Ashford, Elizabeth,
Yoo, Kisook,
Xu, Zhi-Xin,
Loetscher, Hansruedi,
Santarelli, Luca
Background: Gantenerumab is a fully human anti-Aβ monoclonal antibody in clinical development for the treatment of Alzheimer disease (AD).; Objectives: To investigate whether treatment with gantenerumab leads to a measurable reduction in the level of Aβ amyloid in the brain and to elucidate the mechanism of amyloid reduction.; Design: A multicenter, randomized, double-blind, placebo-controlled, ascending-dose […]
Cognitive outcomes after sertaline treatment in patients with depression of Alzheimer disease
Munro, Cynthia A.,
Longmire, Crystal Flynn,
Drye, Lea T.,
Martin, Barbara K.,
Frangakis, Constantine E.,
Meinert, Curtis L.,
Mintzer, Jacobo E.,
Porsteinsson, Anton P.,
Rabins, Peter V.,
Rosenberg, Paul B.,
Schneider, Lon S.,
Weintraub, Daniel,
Lyketsos, Constantine G.
Objectives: Although many depressed patients with Alzheimer disease (AD) are treated with antidepressants, the effect of such treatment on cognitive performance in these patients is not known. The authors report cognitive outcomes in patients with depression of AD (dAD) after a 24-week trial of sertraline or placebo.; Design: Placebo-controlled, randomized, double-blind trial.; Setting: Outpatient memory […]
Effects of lexical-semantic treatment on memory in early Alzheimer disease: an observer-blinded randomized controlled trial
Jelcic, Nela,
Cagnin, Annachiara,
Meneghello, Francesca,
Turolla, Andrea,
Ermani, Mario,
Dam, Mauro
Background: Episodic memory and semantic abilities deteriorate early in Alzheimer disease (AD). Since the cognitive system includes interconnected and reciprocally influenced neuronal networks, the authors hypothesized that stimulation of lexical-semantic abilities may benefit semantically structured episodic memory.; Objective: To investigate the effects of lexical-semantic stimulation (LSS) on verbal communication and episodic memory in early AD.; […]
Relapse risk after discontinuation of risperidone in Alzheimer’s disease
Devanand, D. P.,
Mintzer, Jacobo,
Schultz, Susan K.,
Andrews, Howard F.,
Sultzer, David L.,
de la Pena, Danilo,
Gupta, Sanjay,
Colon, Sylvia,
Schimming, Corbett,
Pelton, Gregory H.,
Levin, Bruce
Background: Among patients with Alzheimer’s disease who have had a response to antipsychotic medication for psychosis or agitation-aggression, the risk of a recurrence of symptoms after discontinuation of the medication has not been established.; Methods: Patients with Alzheimer’s disease and psychosis or agitation-aggression received open-label treatment with risperidone for 16 weeks. Those who had a […]
The antipsychotic discontinuation in Alzheimer disease trial: clinical rationale and study design
Devanand, D. P.,
Mintzer, Jacobo,
Schultz, Susan,
Sultzer, David,
de la Pena, Danilo,
Gupta, Sanjay,
Colon, Sylvia,
Schimming, Corbett,
Pelton, Gregory H.,
Andrews, Howard,
Levin, Bruce
Objectives: : Research studies on the effects of discontinuing antipsychotic medications in patients with dementia have not identified specific target symptoms or response to antipsychotics prior to discontinuation. The Antipsychotic Discontinuation in Alzheimer Disease (ADAD) trial addresses these issues in a randomized, double-blind, placebo-controlled, multicenter risperidone treatment and discontinuation trial. In Phase A, AD patients […]